Prime Medicine, Inc.
PRMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. The company carries a $579.8M market cap, placing it firmly in the small-cap category. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Market Cap
$579.8M
Beta
2.36
P/E (TTM)
—
P/E (Fwd)
-3.68
EPS (TTM)
$-1.23
EPS (Fwd)
$-0.87
ROE
-216.1%
ROA
-41.5%
Cash
$135.5M
Total Debt
$114.5M
Free CF
-$78.3M
52W Change
143.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $135.5M in cash comfortably exceeding the $114.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$78.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -216.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.36 means PRME is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRME.